Literature DB >> 17403842

Outcome at 2 years of age of infants from the DART study: a multicenter, international, randomized, controlled trial of low-dose dexamethasone.

Lex W Doyle1, Peter G Davis, Colin J Morley, Andy McPhee, John B Carlin.   

Abstract

OBJECTIVE: Low-dose dexamethasone facilitates extubation in chronically ventilator-dependent infants with no obvious short-term complications. The objective of this study was to determine the long-term effects of low-dose dexamethasone.
METHODS: Very preterm (<28 weeks' gestation) or extremely low birth weight (birth weight <1000 g) infants who were ventilator dependent after the first week of life for whom clinicians considered corticosteroids were indicated were eligible. After informed consent, infants were randomly assigned to masked dexamethasone (0.89 mg/kg over 10 days) or saline placebo. Survivors were assessed at 2 years' corrected age by staff blinded to treatment group allocation to determine neurosensory outcome, growth, and health.
RESULTS: The trial was abandoned well short of its target sample size because of recruitment difficulties. Seventy infants were recruited from 11 centers, 35 in each group: 59 survived to 2 years of age, and 58 (98%) were assessed at follow-up, but data for cerebral palsy were available for only 56 survivors. There was little evidence for a difference in the major end point, the rate of the combined outcome of death, or major disability at 2 years of age (dexamethasone group: 46%; controls: 43%). Rates of mortality before follow-up (11% vs 20%), major disability (41% vs 31%), cerebral palsy (14% vs 22%), or of the combined outcomes of death or cerebral palsy (23% vs 37%) were not substantially different between the groups. There were no obvious effects of low-dose dexamethasone on growth or readmissions to hospital after discharge.
CONCLUSIONS: Although this trial was not able to provide definitive evidence on the long-term effects of low-dose dexamethasone after the first week of life in chronically ventilator-dependent infants, our data indicate no strong association with long-term morbidity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17403842     DOI: 10.1542/peds.2006-2806

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  32 in total

1.  Death or neurodevelopmental impairment at 18 to 22 months corrected age in a randomized trial of early dexamethasone to prevent death or chronic lung disease in extremely low birth weight infants.

Authors:  Ann R Stark; Waldemar A Carlo; Betty R Vohr; Lu Ann Papile; Shampa Saha; Charles R Bauer; William Oh; Seetha Shankaran; Jon E Tyson; Linda L Wright; W Kenneth Poole; Abhik Das; Barbara J Stoll; Avroy A Fanaroff; Sheldon B Korones; Richard A Ehrenkranz; David K Stevenson; Myriam Peralta-Carcelen; Deanne E Wilson-Costello; Henrietta S Bada; Roy J Heyne; Yvette R Johnson; Kimberly Gronsman Lee; Jean J Steichen
Journal:  J Pediatr       Date:  2013-08-27       Impact factor: 4.406

Review 2.  Prevention and management of bronchopulmonary dysplasia: Lessons learned from the neonatal research network.

Authors:  Kathleen A Kennedy; C Michael Cotten; Kristi L Watterberg; Waldemar A Carlo
Journal:  Semin Perinatol       Date:  2016-10       Impact factor: 3.300

3.  Stopping the swinging pendulum of postnatal corticosteroid use.

Authors:  Sara B Demauro; Kevin Dysart; Haresh Kirpalani
Journal:  J Pediatr       Date:  2014-01       Impact factor: 4.406

Review 4.  Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies.

Authors:  Jenny K Koo; Robin Steinhorn; Anup C Katheria
Journal:  J Perinatol       Date:  2021-07-09       Impact factor: 2.521

5.  Pilot randomized trial of hydrocortisone in ventilator-dependent extremely preterm infants: effects on regional brain volumes.

Authors:  Nehal A Parikh; Kathleen A Kennedy; Robert E Lasky; Georgia E McDavid; Jon E Tyson
Journal:  J Pediatr       Date:  2012-11-08       Impact factor: 4.406

6.  Respiratory Support for Very Low Birth Weight Infants Receiving Dexamethasone.

Authors:  Yamini V Virkud; Christoph P Hornik; Daniel K Benjamin; Matthew M Laughon; Reese H Clark; Rachel G Greenberg; P Brian Smith
Journal:  J Pediatr       Date:  2017-01-18       Impact factor: 4.406

Review 7.  Bronchopulmonary dysplasia.

Authors:  Bernard Thébaud; Kara N Goss; Matthew Laughon; Jeffrey A Whitsett; Steven H Abman; Robin H Steinhorn; Judy L Aschner; Peter G Davis; Sharon A McGrath-Morrow; Roger F Soll; Alan H Jobe
Journal:  Nat Rev Dis Primers       Date:  2019-11-14       Impact factor: 52.329

Review 8.  Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants.

Authors:  Lex W Doyle; Jeanie L Cheong; Richard A Ehrenkranz; Henry L Halliday
Journal:  Cochrane Database Syst Rev       Date:  2017-10-24

Review 9.  Predictors of bronchopulmonary dysplasia.

Authors:  Andrea Trembath; Matthew M Laughon
Journal:  Clin Perinatol       Date:  2012-09       Impact factor: 3.430

10.  Postnatal corticosteroids for bronchopulmonary dysplasia.

Authors:  Alan H Jobe
Journal:  Clin Perinatol       Date:  2009-03       Impact factor: 3.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.